Atreca to Present at the Stifel 2016 Healthcare Conference

REDWOOD CITY, Calif.--()--Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today that Tito Serafini, Ph.D., President, Chief Executive Officer, and Co-Founder, will present at the Stifel 2016 Healthcare Conference on Wednesday, November 16, 2016 at 8:45 a.m. Eastern Time at the Lotte New York Palace Hotel. Dr. Serafini will provide an overview of Atreca and business update.

About Atreca, Inc.

Atreca is a privately held biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-cancer immune responses. Atreca is able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T-cell receptors, and targets that are key to successful treatment outcomes. Atreca’s proprietary Immune Repertoire Capture™ (IRC™) technology profiles a patient’s immune response at the single-cell level at very high throughput without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates with the objective of enhancing engagement of the human immune response in cancer treatment and other indications, thus optimizing therapeutic outcomes. For more information on Atreca, please visit www.atreca.com.

Contacts

Atreca, Inc.:
Susan Berland
EVP and Chief Financial Officer
info@atreca.com
or
Media:
Justin Jackson, 212-213-0006, ext. 327
jjackson@burnsmc.com

Contacts

Atreca, Inc.:
Susan Berland
EVP and Chief Financial Officer
info@atreca.com
or
Media:
Justin Jackson, 212-213-0006, ext. 327
jjackson@burnsmc.com